ReviewTherapeutic advances in gastroenterology2021
Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review.
Review in Therapeutic advances in gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06676488 (A Randomized Crossover Trial of Bright Light Therapy in Irritable Bowel Syndrome), which is not on this map. Cited by 130 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Crossover Trial of Bright Light Therapy in Irritable Bowel Syndrome
Who cites it
130 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.
- Constipation is associated with an increased risk of depression: A systematic review and meta-analysis of observational studies.Translational psychiatry · 2026Pooled it
- Trial
- Acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research model.Gut microbes · 2025Trial
- Elevated Fecal Biomarkers of Colo-Rectal Epithelial Cell Activity in Irritable Bowel Syndrome.Neurogastroenterology and motility · 2025Trial
- Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with Constipation.Digestive diseases (Basel, Switzerland) · 2025Trial
- Yunpi Rougan Prescription in Treating Constipation-Predominant IBS: Clinical Observation and Gut Microbiota Effects.Combinatorial chemistry & high throughput screening · 2025Trial
- Eight weeks of treatment with probioticFrontiers in nutrition · 2025Trial
- Trial
- Effect of a Multistrain Probiotic on Leaky Gut in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study.Digestive diseases (Basel, Switzerland) · 2023Trial
- Lactiplantibacillus Plantarum CKDB008 and Lacticaseibacillus Rhamnosus LDTM7511 Attenuate Visceral Hypersensitivity and Suppress Serum IgE in an Acetic Acid-Induced IBS-Like Rat Model.Probiotics and antimicrobial proteins · 2026Article
- Functional enhancement of traditional taralli through lentil hulls and tritordeum flour integration: nutritional, metabolomic, and sensory insights.Food chemistry: X · 2026Article
- The minor spliceosome component U4atac regulates JAK/STAT signaling to modulate hematopoiesis and immune responses in Drosophila melanogaster.Nature communications · 2026Article
- The Impact of Irritable Bowel Syndrome on Spine Surgery Outcomes: A Comprehensive Narrative Review.Journal of clinical medicine · 2026Review
- Preventive and therapeutic effects of co-administration of Bacteroides thetaiotaomicron and infliximab on dextran sodium sulfate-induced colitis in mice.Intestinal research · 2026Article
- Association of IBS-associated E. coli strains with epithelial inflammatory responses and tight junction dysregulation in Caco-2 cells.BMC research notes · 2026Article
- Carotenoids modulate fermentation of inulin ex vivo in IBS and overweight adult gut microbiota.BMC microbiology · 2026Article
- Impact of Fermented Dairy on Gastrointestinal Health and Associated Biomarkers.Nutrition reviews · 2026Review
- Research Progress on the Role ofBiology · 2026Review
- Long-Term Risk of Parkinson's Disease Following Irritable Bowel Syndrome: A Nationwide Population-Based Cohort Study.Healthcare (Basel, Switzerland) · 2026Article
- Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimIrritable bowel syndrome (IBS) is a complex and heterogeneous disorder. Sensory, motor and barrier dysfunctions are the key physiological endophenotypes of IBS. Our aim is to review studies evaluating barrier dysfunction in adults and children with IBS, as well as to link those changes with IBS symptomatology and quality of life.
methodsA comprehensive and systematic review of multiple databases was performed up to March 2020 to identify studies comparing intestinal permeability in IBS patients with healthy controls. Both
resultsWe identified 66 studies, of which 27 used intestinal probes to quantify barrier function. The prevalence of barrier dysfunction differed between PI-IBS (17-50%), IBS-D (37-62%) and IBS-C (4-25%). At a group level, permeability was increased compared with healthy controls in IBS-D (9/13 studies) and PI-IBS (4/4 studies), but only a minority of IBS-C (2/7 studies) and not in the only IBS-M study. All four studies in children with IBS demonstrated loss of barrier function. A heterogeneous set of tight junction genes were found to be altered in small and large intestines of adults with IBS, but these have not been evaluated in children. Positive associations were identified between barrier dysfunction and bowel disturbances (6/9 studies), abdominal pain (9/13 studies), overall symptom severity (1/6 studies), depression and anxiety (1/1 study) and quality of life (1/4 studies). Fecal slurry or supernatants of IBS patients were found to induce barrier disruption in animal models (5/6 studies).
conclusionsBarrier dysfunction is present in a significant proportion of adult and all pediatric IBS studies, especially in the IBS-D and PI-IBS subtype. The majority of studies indicated a positive association between loss of barrier function and symptoms such as abdominal pain and changes in the bowel function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.